The biotech IPO train is rolling on without slowing as we head into a holiday weekend. The latest to lay the groundwork to go public are Sutro Biopharma and Arvinas, which both want Wall Street’s help to back human trials of experimental cancer drugs.
South San Francisco, CA-based Sutro set a preliminary $75 million target in the IPO paperwork it filed on Thursday. Sutro has applied for a listing on the Nasdaq under the stock symbol “STRO.”
Sutro will use the IPO cash to fund its two lead cancer drugs, STRO-001 and STRO-002. Both are antibody drug conjugates, a type of… Read more »
UNDERWRITERS AND PARTNERS